Loading…
Based on limited metadata, this FDA Warning Letter issued to Jubilant Generics Limited on March 6, 2019, concerns drug manufacturing or quality practices. While the specific violations cannot be detailed without access to the full letter text, the warning was issued through the FDA's drug regulatory authority. The letter likely addressed manufacturing, quality control, or compliance issues related to pharmaceutical drug products, though the exact nature of the violations is not available in the metadata provided.